Regen BioPharma Inc
Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. The company engages in identifying small molecules that inhibit or express NR2F6, leading to immune cell activation for oncology applications and immune cell suppression for autoimmune diseases. It also develops several products: HemaXellarate, a cellular therapeutic product derived from au… Read more
Market Cap & Net Worth: Regen BioPharma Inc (RGBP)
Regen BioPharma Inc (PINK:RGBP) has a market capitalization of $7.88 Million ($7.88 Million) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #40212 globally and #13061 in its home market, demonstrating a 21.31% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Regen BioPharma Inc's stock price $0.06 by its total outstanding shares 129468577 (129.47 Million).
Regen BioPharma Inc Market Cap History: 2015 to 2025
Regen BioPharma Inc's market capitalization history from 2015 to 2025. Data shows change from $15.05 Billion to $7.88 Million (-55.69% CAGR).
Regen BioPharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Regen BioPharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
33.33x
Regen BioPharma Inc's market cap is 33.33 times its annual revenue
1740.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $7.96 Billion | $100.00K | -$3.41 Million | 79623.17x | N/A |
| 2017 | $4.95 Billion | $110.00K | -$5.84 Million | 45019.76x | N/A |
| 2018 | $271.88 Million | $100.00K | -$4.71 Million | 2718.84x | N/A |
| 2019 | $19.42 Million | $110.00K | -$2.62 Million | 176.55x | N/A |
| 2020 | $97.10 Million | $110.00K | $2.73 Million | 882.74x | 35.55x |
| 2021 | $1.42 Billion | $171.19K | -$6.76 Million | 8281.14x | N/A |
| 2022 | $378.70 Million | $235.52K | $2.23 Million | 1607.93x | 170.05x |
| 2023 | $61.50 Million | $236.56K | $1.02 Million | 259.97x | 60.06x |
| 2024 | $7.13 Million | $236.56K | -$867.25K | 30.16x | N/A |
| 2025 | $7.88 Million | $236.56K | -$1.27 Million | 33.33x | N/A |
Competitor Companies of RGBP by Market Capitalization
Companies near Regen BioPharma Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Regen BioPharma Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Regen BioPharma Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Regen BioPharma Inc's market cap moved from $15.05 Billion to $ 7.88 Million, with a yearly change of -55.69%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $7.88 Million | +10.53% |
| 2024 | $7.13 Million | -88.40% |
| 2023 | $61.50 Million | -83.76% |
| 2022 | $378.70 Million | -73.29% |
| 2021 | $1.42 Billion | +1360.00% |
| 2020 | $97.10 Million | +400.00% |
| 2019 | $19.42 Million | -92.86% |
| 2018 | $271.88 Million | -94.51% |
| 2017 | $4.95 Billion | -37.80% |
| 2016 | $7.96 Billion | -47.10% |
| 2015 | $15.05 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Regen BioPharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.88 Million USD |
| MoneyControl | $7.88 Million USD |
| MarketWatch | $7.88 Million USD |
| marketcap.company | $7.88 Million USD |
| Reuters | $7.88 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.